Lajos Pusztai, MD | Authors

Articles

Pembrolizumab Shows EFS Benefit in TNBC Without Complete Response

October 27, 2022

Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.

Efficacy of Neoadjuvant/Adjuvant Pembrolizumab in TNBC

June 16, 2022

Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.

The Potential Role of Immunotherapy in the Management of Breast Cancer

October 03, 2016

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.